journal article·2016-08-17Open access

In vitro and in vivo evaluation of PEGylated nanoparticles of bendamustine for treatment of lung cancer

Pooja Dubey, Bina Gidwani, Ravindra Pandey, Shiv Shankar Shukla

Abstract

The purpose of this study was to develop PEGylated nanoparticles of bendamustine (BM) to improve therapeutic efficiency of drug and reduce the side-effects. The nanoparticles were prepared by a modified diffusion-emulsification method. The particle size and zeta potential of optimized BM-loaded PEGylated NPs were found to be 256 nm and -29.1 mV. The in vitro release showed biphasic behavior, with initial burst release followed by slow sustained delivery. The anti-tumor activity was determined using the A- 549 cell line, by the MTT assay. The stability study revealed that the nanoparticles prepared were stable for 3 months at both 25°C and 4°C.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Columbia Institute of Pharmacy

University Institute of Pharmacy, Pandit Ravishankar Shukla University

References (20)

Show source-provided references
1. 10.3109/03639045.2011.57516210.3109/03639045.2011.575162 ↗
2. 10.1016/j.jconrel.2008.09.08610.1016/j.jconrel.2008.09.086 ↗
3. 10.1053/sonc.2002.3487210.1053/sonc.2002.34872 ↗
4. 10.1016/j.jconrel.2007.06.01010.1016/j.jconrel.2007.06.010 ↗
5. Gidwani B, Vyas A. 2014. Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. Pharm Dev Technol. 1–11.
6. 10.3109/21691401.2015.100850310.3109/21691401.2015.1008503 ↗
7. 10.1002/jgm.86810.1002/jgm.868 ↗
8. 10.1186/1556-276X-9-36310.1186/1556-276X-9-363 ↗
9. 10.1016/j.jconrel.2005.06.00610.1016/j.jconrel.2005.06.006 ↗
10. 10.1016/S0168-3659(02)00320-610.1016/S0168-3659(02)00320-6 ↗
11. 10.1016/j.nano.2008.08.00310.1016/j.nano.2008.08.003 ↗
12. 10.1016/j.nano.2009.02.00210.1016/j.nano.2009.02.002 ↗
13. 10.1158/1078-0432.CCR-04-077010.1158/1078-0432.CCR-04-0770 ↗
14. 10.3109/21691401.2014.95510810.3109/21691401.2014.955108 ↗
15. 10.1016/j.jconrel.2007.01.01810.1016/j.jconrel.2007.01.018 ↗
16. Travis WD, Travis LB, Devesa SS. 1995. Lung cancer incidence and survival by histological type. Lung Canc. 75:191–202.
17. 10.1111/j.1349-7006.1996.tb03113.x10.1111/j.1349-7006.1996.tb03113.x ↗
18. United States, National Institutes of Health, Cancer Therapy Evaluation Program (ctep). 2011. Common Toxicity Criteria (CTC).
19. WHO Disease and injury country estimates. 2009. WHO fact sheet on cancer.
20. 10.1016/j.jconrel.2004.01.01010.1016/j.jconrel.2004.01.010 ↗